Zacks Investment Research on MSN2h
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired ...
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.
US close: Uncertainty rattles markets as hectic tariff campaign continues
A step-up in protectionist threats between Canada and the US prompted another negative session on Wall Street on Tuesday, ...
Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a seven-day winning streak.
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...